Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling
Atrial Fibrillation
About this trial
This is an interventional prevention trial for Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria: with non-valvular paroxysmal atrial fibrillation (AF that terminates spontaneously or with intervention within seven days of onset). Patient age 18-60 years. Patients with Glomerular Filtration Rate (GFR) >45 ml/min/1.73m2 (Cockcroft-Gault equation). Patient with normal left atrium or dilated (diameter <5 cm) Exclusion Criteria: Patients < 18 yrs old. Patients with valvular heart diseases (Moderate to severe MS, severe AS, Prosthetic heart valves). Patients with left atrium > 5cm. Patients with glomerular Filtration Rate (GFR) <45 ml/min/1.73m2 (Cockcroft-Gault equation). Patient with ischemic heart disease (previous MI, UA, PCI or CABG). Patient with previous ischemic stroke.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Dapagliflozin
Placebo
patients who will receive SGLT2 inhibitors
Patients who will receive Rhythm control +/- oral anticoagulation